EODData

MEMBERSHIP REGISTER LOG IN

FRA, 7AY1: ACTINIUM PHARMAC. DL-001

22 May 2026
LAST:

0.9910

CHANGE:
 0.01		OPEN:
0.9910		HIGH:
0.9910		ASK:
0.0000		VOLUME:
0
CHG(%):
1.02		PREV:
0.9810		LOW:
0.9910		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 May 260.99100.99100.99100.99100
21 May 260.98100.98100.98100.98100
20 May 260.96700.96700.96700.96700
19 May 260.97900.97900.97900.97900
18 May 261.04601.04601.04601.04600
15 May 261.07001.07001.07001.07000
14 May 261.07401.07401.07401.07400
13 May 261.08001.08001.08001.08000
12 May 261.11201.13001.11201.13000
11 May 261.08401.08401.08401.08400

PROFILE

Name:ACTINIUM PHARMAC. DL-001
About:Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:100 Park Avenue, New York, NY, United States, 10017
Website:https://www.actiniumpharma.com
ISIN:US00507W2061

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.07 
Forward P/E:-1.47 
PEG Ratio:0.02 
Price to Sales:493.15 
Price to Book:3.64 
Operating Margin:-63.24 
Return on Assets:-0.34 
Return on Equity:-1.33 
Revenue:76.4K 
Shares:31.2M 
Market Cap:30.92M 

TECHNICAL INDICATORS

MA5:0.990.2%
MA10:1.045.0%
MA20:1.034.3%
MA50:0.990.2%
MA100:1.023.1%
MA200:1.1616.9%
STO9:14.72 
STO14:26.84
RSI14:53.10
WPR14:-73.16
MTM14:0.05
ROC14:0.05 
ATR:0.03 
Week High:1.078.0%
Week Low:0.972.5%
Month High:1.2526.5%
Month Low:0.9416.9%
Year High:1.6566.3%
Year Low:0.8319.8%
Volatility:24.86 

RECENT SPLITS

Date Ratio
11 Aug 20201-30